T he use of surgical treatments for movement disorders has been well established for several decades, with a strong focus, in the past, on ablative lesioning procedures and, more recently, deep brain stimulation. Magnetic resonance imaging (MRI)-guided focused ultrasound (MRgFUS) is emerging as a newly recognized surgical technique for the treatment of various movement disorders. The most robust data, demonstrating safety and efficacy of MRgFUS, have been published in trials directed at treatment of essential tremor (ET); however, many trials are underway to define its role in other movement disorders, such as Parkinson's disease with preliminary results echoing those from studies in ET. The full potential for use of MRgFUS, both in the field of movement disorders and beyond, is only beginning to be explored.
Introduction of technology
FUS is emerging as a newly recognized surgical option in the field of movement disorders. Though robust trials studying the clinical application of MRgFUS have only recently been carried out, its roots date back to the 1950s when the Fry brothers of Illinois described use of ultrasound energy for precise lesioning of the internal capsule of cats. 1 While this technique initially required craniectomy for accurate energy focusing, the advent of a phased array transducer has allowed for an incisionless procedure with retained precision.
The technique for use of MRgFUS has become largely standardized. A patient's head is shaved to avoid possible heat trapping between hair and scalp and a water-filled elastic cap is placed over the scalp. Lesions are targeted using 1,024 ultrasonic transducers arranged in a hemispheric orientation ( Figure 1 ). The utility of MRgFUS as a lesioning technique is based on studies showing that tissue changes occur when temperatures reach 55-65°C. 2 In practice, initial energy pulses are applied to reach a non-ablative temperature of 40-45°C. Lesion accuracy is determined by clinical examination of the patient while temperature monitoring is provided through MRI thermometry. This precision, along with the ability to monitor treatment effect in real-time, have made MRgFUS an attractive tool for treatment of multiple movement disorders with the most robust data emerging from trials in ET.
Essential tremor
ET is one of the most common movement disorders worldwide estimated to affect almost 5% of individuals over 65 years old. 4 The tremor is fast frequency (4-12 Hz) with postural and kinetic components; it primarily affects the arms but can involve the head, voice, trunk, and legs. 5 While the diagnosis does not shorten a person's lifespan, the tremor can impair function, lead to disability The Use of Magnetic Resonance Imaging-guided Focused Ultrasound in Movement Disorders and diminish overall quality of life. Pharmacologic therapy includes first-line agents propranolol and primidone, and second-line agents including topiramate, gabapentin, atenolol, alprazolam, and others. 6 While medication is effective for most patients with ET, large population studies have suggested that 25-50% of ET is refractory to medication. 5 Stimulation and ablation of the thalamic ventral intermediate nucleus (Vim) has been shown to effectively reduce tremor in ET. 7 Multiple trials report clinical improvement of ET following radiofrequency thalamotomy, 8, 9 gamma knife radiosurgery [10] [11] [12] [13] and DBS. 14 Comparison studies of these varying techniques are limited. Schuurman et al.'s randomized study comparing unilateral radiofrequency thalamotomy versus bilateral DBS in patients with PD, ET, or multiple sclerosis suggests that thalamic stimulation is more effective with regard to tremor suppression than thalamotomy with a lower overall rate of adverse events; however, one mortality was reported in the stimulation group related to intracerebral hematoma. 9 The morbidity associated with historical surgical techniques has led to exploration of additional procedural tools. Participants additionally reported a 45.5% improvement in fine motor tasks (writing, drawing), and 51.1% reduction in subjective functional disability at 3 months. The adverse effects included persistent finger paresthesias in one patient at 3 months, and a deep venous thromboembolism 1 week after the procedure in another patient. 15 Chang et al. published a feasibility trial, in which 11 participants were recruited to undergo unilateral focused-ultrasound thalamotomy. Of the 11 participants, only eight reached therapeutic temperature. These patients were followed for 6 months at which time they reported improvement in these symptoms did not persist in the majority of patients at 12 months (9% and 14%, respectively). 18 This study was the first to provide robust data demonstrating the effect of MRgFUS thalamotomy, with sustained improvements noted in tremor severity, disability, and quality of life.
Though FUS has proven to be safe and effective for unilateral thalamotomy in patients with ET, further work will be required to determine durability of benefit. With this consideration, it will also be important to see if tremor re-emerges and if retreatment with MRgFUS thalamotomy has value. While lesioning procedures have typically been used for unilateral treatments only, understanding the safety and therapeutic effects of bilateral lesioning may be explored in the future. As such, comparing concurrent versus The pallidothalamic tract was targeted with the first group of patients receiving a single application of ultrasound energy, and the second group receiving multiple applications of energy (four to five in total). Follow-up examinations were performed at 3 months. This study demonstrated that repeated application of energy allowed for more sustained effects with a 60.9% mean total Unified Parkinson's Disease Rating Scale (UPDRS) score reduction noted in the second group, versus 7.6% reduction in the first group at 3 months. 23 There were no procedure-related side effects reported in either group. Based on the Mini Mental Status Test and the Hospital Anxiety and Depression Scores, there was no change in mood or cognition pre and post procedure for either group.
Schlesinger et al. studied seven patients with moderate to severe Parkinson tremor, performing unilateral FUS Vim thalamotomy to the side with most severe tremor. 24 Patients were followed for 3-12 months. Results showed a significant improvement at 1 week on the mean UPDRS (from 37.4±12. Prior studies in the PD population have suggested that cognition may be affected following thalamotomy, particularly when performed in the left hemisphere. 26 This risk for this effect following MRgFUS thalamotomy is currently unknown but will be important to study in the future.
Subthalamic nucleus
The anti-tremor effects of either ablation or stimulation of the STN have historically made it an attractive target for functional neurosurgery in PD.
Prior reviews have suggested that unilateral subthalamotomy not only improves the cardinal features of PD in the on and off medication states, but additionally allows for a substantial decrease in the daily requirement of levodopa, thereby often leading to decreased dyskinesia. Side effects from unilateral STN ablation can include hemiballismus/hemichorea and postural instability, though these are typically transient. 27 The effects of FUS on the STN are unclear at this time but multiple trials are currently under way to explore this (ClinicalTrials.gov Identifiers: NCT02003248 and NCT02252380). As of yet, there are no published preliminary data from these studies available.
Globus pallidus
The GPi has been a favored target for lesioning and DBS particularly due its effects on suppressing dyskinesia in PD, though there is also well characterized benefit in bradykinesia and rigidity. A case report from Na et al. has demonstrated safety and efficacy of FUS pallidotomy in a single patient with PD with sustained effects 6 months later. This patient experienced an 80% reduction in the UPDRS Part I score, a 51% reduction in the Part II score, and a 60% and 54% reduction in the Part III score "on" and "off" medication, respectively, by 6 months. No adverse effects of the procedure were documented. 28 A multicenter feasibility trial is currently underway exploring unilateral FUS-guided lesioning of the globus pallidum for medically-refractory dyskinesias in advanced PD.
Use of focused ultrasound in other movement disorders
There is limited data, at present, for the use of FUS in less common 29 One case report demonstrated efficacy of MRgFUS in tremor associated with Fragile X tremor ataxia syndrome (FXTAS). 30 There are no trials published evaluating MRgFUS in the treatment of chorea.
The future of focused ultrasound Low-intensity focused ultrasound
While high-intensity FUS lesioning has received the most recent attention, research into low-intensity FUS (LIFUS) is gaining momentum in the field of neuromodulation. Though multiple modalities for neural stimulation are currently available, they either require an invasive surgery (in the case of DBS and vagal nerve stimulation) or lack target specificity (in the case of transcranial magnetic stimulation and cranial electrotherapy stimulation). LIFUS could provide a non-invasive precise targeting technique for neuromodulation. While the exact mechanism of LIFUS is unknown, prior studies have suggested that lower power sonications can cause either inhibitory or excitatory effects which are reversible. 31 The threshold for thermal ablation is not met with lower intensity sonications. Tufail et al. observed clinical motor contraction following stimulation of the motor cortex of mice, 32 while others have described reversible suppression of visual-evoked potentials using LIFUS. 32 The potential uses of LIFUS not only in neuromodulation but also brain mapping suggest that this is a novel and emerging technology; however, the efficacy and duration of effect of this technique is currently unknown.
Use of focused ultrasound in other diseases
FUS is not only under review for use in multiple movement disorders, but is being applied as a treatment for many other neurologic and non-neurologic diseases. These include, but are not limited to, treatment of neuropathic pain, 3 tumor ablation, 34 and sonothrombolysis for stroke therapy. 35 MRgFUS is also being studied as a means for drug delivery across the blood-brain barrier, which may have implications for treating brain tumors, demyelinating disorders, neuroinflammatory conditions, and other disorders where targeted therapy may be indicated. 38 Larger studies will be required to define, not only the role of MRgFUS for these rarer diseases and the long-term effects of unilateral versus bilateral lesioning, but also the role of this treatment vis-à-vis currently utilized and effective therapies such as DBS.
